Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of EA2192 and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. Staff at sites participating in the EA2192/APOLLO trial may also use this content on their own institutions’ marketing/communications channels.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
Twitter: <https://twitter.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
YouTube (*video only*): <https://www.youtube.com/channel/UCAC_V1QdqlH2KdHOt7K2IHw>

Target Audience(s)  
The pancreatic cancer community, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

**EA2192**

*A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation*

**Why consider participating in this study?**

* Research studies are an important way to test the effectiveness of new therapies and approaches for treating pancreatic cancer.
* The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.
* The purpose of EA2192 / APOLLO is to compare the usual approach (monitoring/observation) to treatment for one year with a drug called olaparib, in patients with *BRCA* or *PALB2* mutations.
* EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of observation.

**What does this study involve?**

* If you decide to participate in EA2192 / APOLLO, you will be assigned by chance (randomized) to one of the groups listed below. Neither you nor your doctor will be told which group you are in. Each patient has a 2/3 chance of being in Group 1 and a 1/3 chance of being in Group 2.
* **Group 1:** You will get a study drug called olaparib, which is a tablet. You will take two tablets by mouth twice daily for 12 months.
* **Group 2:** You will get a tablet that looks like the study drug, but contains no medication (this is called a placebo). You will take two placebo tablets by mouth twice daily for 12 months.

A computer program with arrows

Description automatically generated with medium confidence

* After you finish your study treatment, your doctor will continue to follow your condition every 8 weeks for up to 10 years.

**Who will take part in this study?**

* Approximately 152 patients will participate in EA2192 / APOLLO.
* Participants must have a mutation (as identified in saliva, blood, and/or tumor tissue samples) in one of the following genes in order to participate in EA2192 / APOLLO: *BRCA1, BRCA2* or *PALB2*.
* You can decide to stop taking part in the study at any time, even after you have enrolled.

**What are the costs of taking part in this study?**

* Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study. Check with your insurance company to find out what they will pay for.
* You/your insurance provider will **NOT** have to pay for olaparib while you take part in EA2192/APOLLO.
* Taking part in this study may mean that you need to visit the clinic or hospital more often than if you were getting the usual treatment for your cancer.
* You will not be paid for taking part in EA2192/APOLLO.

**How can you learn more or sign up for the trial?**

* About the EA2192 / APOLLO study, talk with your doctor, or:
  + Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EA2192, then select the link to EA2192.
    - For information about medical facilities where the study is available, scroll down the page to Locations and Contacts.
  + Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
* About clinical trials:
  + General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)
  + Insurance coverage: visit [www.cancer.gov/clinicaltrials/learningabout/payingfor](https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying)
* About ECOG-ACRIN:
  + Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
  + For a list of patient resources and links to patient advocacy groups, visit <https://ecog-acrin.org/patients/resources>

Social Media Messaging

|  |  |
| --- | --- |
| **Twitter** | **Facebook/LinkedIn** |
| Do you have #PancreaticCancer with a BRCA1, BRCA2, or PALB2 mutation and resected (surgically removed) pancreatic cancer? If so, you may be able to participate in this study of a potential new treatment. Learn more about the EA2192/APOLLO study: http://bit.ly/apollo-trial #pancsm | Do you have pancreatic cancer with a BRCA1, BRCA2, or PALB2 mutation and resected (surgically removed) pancreatic cancer? If so, you may be able to participate in this study of a potential new treatment. Learn more about the EA2192/APOLLO study: http://bit.ly/apollo-trial |
| Learn about the EA2192/APOLLO study, treating patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. More information: http://bit.ly/apollo-trial #pancsm #pancaware | Learn about the EA2192/APOLLO study, treating patients with pancreatic cancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. More information: http://bit.ly/apollo-trial #pancsm |
| You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: http://bit.ly/apollo-trial #pancsm | You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: http://bit.ly/apollo-trial #pancsm |

**Hashtags:** #PancreaticCancer#pancaware #PanCan #pancsm #PancChat

Sample Imagery

A person looking at a person on a device

Description automatically generated

A group of women looking at a device

Description automatically generated